Kelley A. Fedler

Kelley A. Fedler

Auto-generated profile, based on publicly available information

Kelley A. Fedler

JMI Laboratories , North Liberty, Iowa

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
ABAdam Belley
Adam Belley
MHMichael D Huband
Michael D Huband
KFKelley A. Fedler
Kelley A. Fedler
AWAmy A. Watters
Amy A. Watters
RFRobert K. Flamm
Robert K. Flamm
PKPhilipp Knechtle
Philipp Knechtle
Third-generation cephalosporin resistance among Enterobacteriaceae , mediated by the spread of extended-spectrum β-lactamases (ESBLs), is a very serious medical concern with limited therapeutic options. Enmetazobactam (formerly AAI101) is a novel penicillanic sulfone β-lactamase inhibitor active against a wide range of ESBLs. The combination of enmetazobactam and cefepime has entered phase 3 development in patients with complicated urinary tract infections.

25 March 2020 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
HSHelio S. Sader
Helio S. Sader
PRPaul R. Rhomberg
Paul R. Rhomberg
SCSukantha Chandrasekaran
Sukantha Chandrasekaran
MTMarisol Trejo
Marisol Trejo
KFKelley A. Fedler
Kelley A. Fedler
DDDaniel J. Diekema
Daniel J. Diekema
We assessed the ceftazidime-avibactam disk diffusion breakpoints that provide the lowest discrepancy error rates by testing an Enterobacterales isolate collection with ceftazidime-avibactam MIC values near the breakpoints. Isolates ( n = 112) were susceptibility tested by broth microdilution and disk diffusion methods in 3 laboratories. Current disk diffusion breakpoints (≥21/≤20 mm for susceptible/resistant) provided the lowest error rates, but confirmatory MIC testing is indicated for isolates with inhibition zones of 20 to 22 mm.

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
MCMariana G Castanheira
Mariana G Castanheira
DSDee Shortridge
Dee Shortridge
KFKelley Fedler
Kelley Fedler
CCCecilia G. Carvalhaes
Cecilia G. Carvalhaes
Burkholderia species can cause chronic and often severe respiratory tract infections in cystic fibrosis (CF) patients. The treatment of infections Burkholderia isolates is complicated by low cell permeability to most antimicrobial agents, presence of beta-lactamases and expression of efflux systems. We evaluated the activity of meropenem-vaborbactam (MEV) and comparator agents tested against Burkholderia spp. isolates collected during a surveillance study. A total of 328 Burkholderia spp. isolates were received as part of a global surveillance program from 2014 to 2022. Isolates were identified using MALDI-TOF MS and included B. cenocepacia (11), B. cepacia species complex (BCC; 268), B. gladioli (28) and B. multivorans (21). Isolates were susceptibility (S) tested by reference broth microdilution methods and CLSI interpretative criteria was applied for comparator agents for BCC isolates. Meropenem (MEM) alone breakpoints published by CLSI for BCC or EUCAST for Pseudomonas aeruginosa breakpoints were applied for MEV for comparison purposes. MEV (MIC50/90, 1/2 mg/L) inhibited 95.1% of the BCC isolates at ≤4 mg/L and 97.0% at ≤8 mg/L. Trimethoprim-sulfamethoxazole (T/S), MEM and ceftazidime (CAZ) were active against 87.7%, 86.9% and 84.3% of the BCC isolates, respectively and levofloxacin and minocycline inhibited 63.4% and 82.5% of BCC isolates, respectively. Against B. multivorans (21), MEV (MIC50/90, 0.5/2 mg/L) inhibited 95.2% of the isolates at ≤4 mg/L or ≤8 mg/L while MEM inhibited 71.4% of the isolates at ≤4 mg/L and 95.2% of the isolates at ≤8 mg/L. T/S and CAZ were active against 71.4% and 81.0% of the B. multivorans isolates. T/S MEV, MEM and CAZ were active against all 11 B. cenocepacia isolates. MEM and MEV (MIC50/90, 0.5/2 mg/L) exhibited the same activity against 28 B. gladioli isolates. Chronic pulmonary infections caused by Burkholderia spp. isolates can lead to respiratory failure which is the primary cause of mortality and morbidity in CF patients. Despite the elevated susceptibility rates for the therapies of choice for these isolates, T/S, CAZ and MEM resistant isolates have been reported. MEV demonstrated good activity against BCC isolates that are commonly recovered from CF patients. Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Entasis: Grant/Research Support|Melinta: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Dee Shortridge, PhD, Melinta: Grant/Research Support|Shionogi: Grant/Research Support Kelley Fedler, BS, Melinta: Grant/Research Support|Paratek: Grant/Research Support Cecilia G. Carvalhaes, MD, PhD, AbbVie: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
MHMichael D Huband
Michael D Huband
MPMichael Pfaller
Michael Pfaller
KFKelley Fedler
Kelley Fedler
HSHelio S. Sader
Helio S. Sader
MCMariana G Castanheira
Mariana G Castanheira
876 bacterial isolates from bone/joint infections were received from 39 medical centers in the USA and 16 European countries (2015–2022). Identifications were confirmed by MALDI-TOF MS. The top BJI pathogen was staphylococci (53.4% of all isolates), including S. aureus (47.3%). Other organism groups included streptococci (13.6%), enterococci (7.5%), and Enterobacterales (18.5%). MIC testing of OMC and comparators was conducted according to CLSI M07 (2018) and M100 (2023) guidelines. MIC results were interpreted using FDA or CLSI breakpoints. OMC demonstrated potent in vitro activity against S. aureus (MIC50/90, 0.12/0.25 mg/L; 98.3% susceptible [S]) isolates from BJI, including MRSA (96.5%S) and coagulase-negative staphylococci (MIC50/90, 0.12/0.5 mg/L; 96.3%S) (Table). All (100%) S. pyogenes (MIC50/90, 0.06/0.12 mg/L), 98.4% of Enterococcus spp. (MIC50/90, 0.12/0.25 mg/L), and 84.9% of other streptococci (MIC50/90, 0.12/0.25 mg/L) were S to OMC, whereas comparator agent susceptibilities ranged from 20.3% to 57.9%S. Against Gram negatives, ≥90.0% of Acinetobacter spp. (MIC50/90, 0.5/4 mg/L; 92.3%S), Citrobacter spp. (MIC50/90, 1/2 mg/L; 92.3%S), E. coli (MIC50/90, 0.5/2 mg/L; 100%S), Klebsiella spp. (MIC50/90, 1/4 mg/L; 93.3%S), and S. maltophilia (MIC50, 2 mg/L; 100%S) isolates were S to OMC (FDA breakpoints applied to similar organism groups for comparison). Comparator agent susceptibilities ranged from 46.2%S to 100%S against these organism groups. OMC demonstrated potent in vitro activity against staphylococci, streptococci, enterococci, and Gram-negative isolates from bone/joint infections, with activity generally more potent than or equal to the other tetracycline class comparator agents. Michael D. Huband, BS, BARDA: This study has been funded in part by BARDA under Contract No. 75A50120C00001.|Entasis: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support Michael A. Pfaller, MD, Paratek: Grant/Research Support Kelley Fedler, BS, Melinta: Grant/Research Support|Paratek: Grant/Research Support Helio S. Sader, MD, PhD, FIDSA, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|Cipla: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Entasis: Grant/Research Support|Melinta: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support